Merck has initiated clinical development of a compound that was discovered as part of a funded research collaboration between Merck and Isis Pharmaceuticals. Merck will pay Isis a $1 million milestone payment based on the initiation of clinical trials. Isis’ senior vice president of research, C. Frank Bennett, Ph.D., commented, “We’re pleased to see Merck advancing this molecule in clinical trials. The compound was created out of our productive collaboration, which took ad...